Therapeutic efficacy of IL-17A antibody injection in preventing the development of colitis associated carcinogenesis in mice.

Abstract Chronic inflammation increases colorectal cancer (CRC) risk as seen in ulcerative colitis (UC). Proinflammatory cytokines play a critical role in mediating the development of colitis associated cancer (CAC). In this study, the therapeutic efficacy of anti-interleukin (IL)-17A by anti-IL-17A antibody injection on the development of CAC was assessed in 1,2-dimethylhydrazine (DMH) plus dextran sulfate sodium (DSS) induced CAC mouse model. The results showed that mice dosed with DMH plus DSS for 10 weeks evoked high degree dysplastic lesion in the large bowel that accompanied with significant increased IL-17A expression, proliferation index and inflammation degree in mice. After anti-IL-17A antibody injection for 2 weeks, the number of tumors, proliferation index and the expression level of IL-17A protein in the large bowel tissues were significantly decreased. Therefore, we concluded that the anti-IL-17A blockade can suppress the development of CAC and is a potential therapeutic agent for the prevention of CAC in colitis mice.